Oral Presentation: Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 at WCLC 2026

Phase 3positiveIvonescimabPembrolizumabPositive

AI Analysis

Summary

Akeso announced positive overall survival results from the Phase III HARMONi-2 registrational study comparing ivonescimab versus pembrolizumab in first-line PD-L1-positive NSCLC patients. The positive data was presented at the 2026 World Conference on Lung Cancer.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

Outcome Details

Positive overall survival results from HARMONi-2 study

Importance:8/10

Sentiment:

0.85

NSCLCOncologyImmunotherapyPhase 3Overall SurvivalRegistrational TrialWCLC 2026

Related Companies

$TRAX $WHEN

Read the original article

Published by PR Newswire Biotech on September 15, 2026 6:14 AM

Read Original